Cannabidiol – berauschend unberauschend?

Skopp, Gisela; Graw, Matthias und Musshoff, Frank (2022): Cannabidiol – berauschend unberauschend? In: Rechtsmedizin, Bd. 32, Nr. 6: S. 501-512

Abstract

Products containing cannabidiol (CBD) are currently very popular. Besides the use of CBD as a co-medication with clobazam for drug-resistant epilepsy in childhood, there are currently only a few clinical studies on therapeutic uses. CBD interacts with numerous molecular targets whereas its affinity to cannabinoid receptors is negligible. The various delivery forms influence bioavailability as well as the window of detection;however, a sufficient number of pharmacokinetic studies covering major metabolites of CBD is not yet available. The analytical methods for determination of CBD include tetrahydrocannabinol (THC), its major metabolites and other cannabinoids. The in vivo conversion of CBD to THC is still an unresolved problem. There are defined analytical tests for CBD-based medications but the safety of other products regarding the THC content is not ensured. Flowers of CBD as plant components of the species Cannabis are subject to the Controlled Substances Act in Germany. For products containing CBD as an isolated compound, the appropriate regulations apply according to the use stated by the manufacturer.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0937-9819
• Sprache: Deutsch